Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Afatinib Dimaleate

FDA-approved product (tablet, oral), marketed as Afatinib Dimaleate, Gilotrif.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Afatinib Dimaleate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Afatinib Dimaleate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Afatinib Dimaleate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

    NCT06804850 · start 2025-01-20

    Registered record
    Registry ID
    NCT06804850
    Conditions
    Head and Neck Cancer
    Interventions
    Tislelizumab; Afatinib; Low dose radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2025-01-20
    Completion
    2026-06-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    InterventionTislelizumab; Afatinib; Low dose radiotherapy
    PhasePhase 2
    Registry statusWithdrawn

  • Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

    NCT06302621 · start 2024-04-17

    Registered record
    Registry ID
    NCT06302621
    Conditions
    Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma
    Interventions
    Afatinib; Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-04-17
    Completion
    2027-12-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma
    InterventionAfatinib; Pemigatinib
    PhasePhase 1
    Registry statusRecruiting

  • Pilot Trial for Treatment of Recurrent Glioblastoma

    NCT05432518 · start 2023-06-27

    Registered record
    Registry ID
    NCT05432518
    Conditions
    Glioblastoma; Recurrent Disease; Recurrent Glioblastoma
    Interventions
    Afatinib; Dasatinib; Palbociclib; Everolimus; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2023-06-27
    Completion
    2027-12-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Recurrent Disease; Recurrent Glioblastoma
    InterventionAfatinib; Dasatinib; Palbociclib; Everolimus +1 more
    PhaseEarly phase 1
    Registry statusRecruiting

  • Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

    NCT05865132 · start 2023-04-06

    Registered record
    Registry ID
    NCT05865132
    Conditions
    Esophagus Squamous Cell Carcinoma
    Interventions
    Palbociclib; Afatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-04-06
    Completion
    2026-04
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophagus Squamous Cell Carcinoma
    InterventionPalbociclib; Afatinib
    PhasePhase 2
    Registry statusUnknown

  • To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

    NCT05818982 · start 2023-02-09

    Registered record
    Registry ID
    NCT05818982
    Conditions
    Advanced Esophageal Squamous Cell Carcinoma
    Interventions
    Afatinib; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-02-09
    Completion
    2026-02
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Esophageal Squamous Cell Carcinoma
    InterventionAfatinib; Irinotecan
    PhasePhase 2
    Registry statusUnknown

  • Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC

    NCT05516589 · start 2022-09-12

    Registered record
    Registry ID
    NCT05516589
    Conditions
    Head and Neck Squamous Cell Carcinoma
    Interventions
    Nab-paclitaxel; Cisplatin; Tislelizumab; Afatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-09-12
    Completion
    2024-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Squamous Cell Carcinoma
    InterventionNab-paclitaxel; Cisplatin; Tislelizumab; Afatinib
    PhasePhase 2
    Registry statusCompleted

  • Antineoplastic Drugs in Elderly Patients

    NCT05467189 · start 2021-01-01

    Registered record
    Registry ID
    NCT05467189
    Conditions
    Cancer
    Interventions
    Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-01-01
    Completion
    2028-06-30
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionBusulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
    PhaseNot recorded
    Registry statusRecruiting

  • AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

    NCT04413201 · start 2020-09-11

    Registered record
    Registry ID
    NCT04413201
    Conditions
    Non-squamous NSCLC
    Interventions
    Afatinib; Osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2020-09-11
    Completion
    2026-12-31
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-squamous NSCLC
    InterventionAfatinib; Osimertinib
    PhasePhase 4
    Registry statusActive not recruiting

  • Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

    NCT04183712 · start 2020-06-01

    Registered record
    Registry ID
    NCT04183712
    Conditions
    Gallbladder Carcinoma
    Interventions
    gemcitabine and oxaliplatin.; Afatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-06-01
    Completion
    2025-12
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGallbladder Carcinoma
    Interventiongemcitabine and oxaliplatin.; Afatinib
    PhasePhase 2
    Registry statusRecruiting

  • The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

    NCT04206787 · start 2020-05-20

    Registered record
    Registry ID
    NCT04206787
    Conditions
    Non-squamous, Non-Small Cell Lung Cancer
    Interventions
    Afatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-05-20
    Completion
    2023-12-22
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-squamous, Non-Small Cell Lung Cancer
    InterventionAfatinib
    PhaseNot recorded
    Registry statusCompleted

  • Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

    NCT04930133 · start 2020-02-24

    Registered record
    Registry ID
    NCT04930133
    Conditions
    NSCLC
    Interventions
    Gilotrif
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-02-24
    Completion
    2021-09-30
    Enrolment
    737

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionGilotrif
    PhaseNot recorded
    Registry statusUnknown

  • Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)

    NCT03695510 · start 2019-01-24

    Registered record
    Registry ID
    NCT03695510
    Conditions
    Head and Neck Neoplasms
    Interventions
    Afatinib Oral Tablet; Pembrolizumab Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-01-24
    Completion
    2022-04-14
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Neoplasms
    InterventionAfatinib Oral Tablet; Pembrolizumab Injection
    PhasePhase 2
    Registry statusCompleted

  • An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

    NCT07271446 · start 2018-09-01

    Registered record
    Registry ID
    NCT07271446
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2023-12-01
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionPB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib
    PhasePhase 1
    Registry statusCompleted

  • E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C

    NCT03623750 · start 2018-07-06

    Registered record
    Registry ID
    NCT03623750
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    EGFR-TK Inhibitor; EGF-PTI; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-07-06
    Completion
    2021-12-14
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionEGFR-TK Inhibitor; EGF-PTI; Cyclophosphamide
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Afatinib in Locally Advanced and Metastatic Chordoma

    NCT03083678 · start 2018-06-21

    Registered record
    Registry ID
    NCT03083678
    Conditions
    Chordoma
    Interventions
    Afatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-21
    Completion
    2025-01-31
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChordoma
    InterventionAfatinib
    PhasePhase 2
    Registry statusCompleted